Gates Center for Regenerative Medicine adds Dr. Valeria Canto-Soler — 4 thoughts

Boulder-based The University of Colorado’s Gates Center for Regenerative Medicine added Valeria Canto-Soler, PhD, to conduct research on developing cell-based treatments for ophthalmological disorders.

Advertisement

Here’s what you should know:

1. In addition, Dr. Canto-Soler was named the director of University of Colorado’s CellSite, the departments ocular stem cell and regeneration research program.

2. She earned her PhD from Buenos Aires, Argentina-based Austral University School of Medicine.

3. After earning her PhD, Dr. Canto-Soler served as a fellow at Baltimore-based Johns Hopkins University.

4. In 2014, Dr. Canto-Soler and a team of researchers developed a miniature human retina in a petri dish with human stem cells. The retina could sense light with functional photoreceptor cells. She believes the research could help develop personalized medicine and drug treatments.

More articles on leadership:
Noted anesthesiologist Dr. William Nelson Walker Jr. passes away: 5 key notes
ASC leader to know: Jeffrey Simmons of Regent Surgical Health
Attention ladies: 3 ways to get a seat at the executive table

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

From fragmentation to operational flow: Solving the healthcare workforce puzzle

Tuesday, August 11
1:00 PM - 2:00 PM CDT

Presenters: Dr. Pat Hunt, QGendaAndrea Daugherty, MHA, CISSP, CHCIO, CDH-E, Arrowhead Regional Medical CenterElizabeth Lindsay-Wood, MBA, CHCIO, CDH-E, Moffitt Cancer CenterDeb Muro, El Camino HealthJohn Tejeda, D.H.A., MLS, MPAS, DFAAPA, LSSBB, FACHE, Vascular and Neuroscience Institute

Advertisement

Next Up in Leadership

Advertisement

Comments are closed.